| Host: |
Rabbit |
| Applications: |
IHC/IF |
| Reactivity: |
Human/Rat/Mouse |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Rabbit polyclonal antibody anti-Ankyrin repeat domain-containing protein 11 (557-607 aa) is suitable for use in Immunohistochemistry and Immunofluorescence research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide. |
| Purification: |
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
| Concentration: |
1 mg/mL |
| Dilution Range: |
IHC-P 1:50-200IF 1:50-200 |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Gene Symbol: |
ANKRD11 |
| Gene ID: |
29123 |
| Uniprot ID: |
ANR11_HUMAN |
| Immunogen Region: |
557-607 aa |
| Specificity: |
This antibody detects endogenous levels of ANR11 at Human |
| Immunogen: |
Synthesized peptide derived from the human ANR11 at the amino acid range 557-607 |
| Function | Chromatin regulator which modulates histone acetylation and gene expression in neural precursor cells. May recruit histone deacetylases (HDACs) to the p160 coactivators/nuclear receptor complex to inhibit ligand-dependent transactivation. Has a role in proliferation and development of cortical neural precursors. May also regulate bone homeostasis. |
| Protein Name | Ankyrin Repeat Domain-Containing Protein 11Ankyrin Repeat-Containing Cofactor 1 |
| Cellular Localisation | NucleusLocalizes To Chromatin During Prometaphase |
| Alternative Antibody Names | Anti-Ankyrin Repeat Domain-Containing Protein 11 antibodyAnti-Ankyrin Repeat-Containing Cofactor 1 antibodyAnti-ANKRD11 antibodyAnti-ANCO1 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
